謝 名宗

Medicine & Life Sciences

1. Hepatocellular Carcinoma 100%
2. pembrolizumab 58%
3. Bismuth 57%
4. Nivolumab 56%
5. Choledocholithiasis 55%
6. Sorafenib 50%
7. Endoscopic Retrograde Cholangiopancreatography 47%
8. Pylorus 46%
9. Amoxicillin 46%
10. Helicobacter pylori 40%
11. Survival 33%
12. Metronidazole 33%
13. Tomography 28%
14. Anti-Bacterial Agents 27%
15. Drug Resistance 27%
16. Therapeutics 26%
17. Drug Therapy 24%
18. Liver 21%
19. Comorbidity 18%
20. Protein-Tyrosine Kinases 16%
21. Levofloxacin 14%
22. Clarithromycin 14%
23. Thrombosis 10%
24. Safety 10%
25. Multivariate Analysis 10%
26. Programmed Cell Death 1 Receptor 8%
27. Infections 8%
28. Odds Ratio 8%
29. Tetracycline Resistance 8%
30. Prospective Studies 7%
31. Breath Tests 7%
32. Costs and Cost Analysis 6%
33. Incidence 5%
34. Urea 5%
35. Duration of Therapy 5%
36. Neoplasms 5%